Assenagon Asset Management
VRTX icon

Assenagon Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Assenagon Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377M Buy
759,564
+222,316
+41% +$98.5M 0.47% 36
2026
Q1 		$240M Sell
537,248
-295,605
-35% -$138M 0.36% 47
2025
Q4 		$378M Buy
832,853
+69,150
+9% +$29.8M 0.52% 32
2025
Q3 		$299M Buy
763,703
+520,949
+215% +$218M 0.41% 42
2025
Q2 		$108M Buy
242,754
+34,614
+17% +$16M 0.16% 131
2025
Q1 		$101M Sell
208,140
-631,532
-75% -$294M 0.17% 106
2024
Q4 		$338M Buy
839,672
+528,029
+169% +$245M 0.55% 27
2024
Q3 		$145M Buy
311,643
+215,448
+224% +$103M 0.27% 63
2024
Q2 		$45.1M Sell
96,195
-226,893
-70% -$98.5M 0.1% 150
2024
Q1 		$135M Buy
323,088
+26,935
+9% +$11.4M 0.32% 56
2023
Q4 		$121M Buy
296,153
+93,922
+46% +$34.7M 0.32% 58
2023
Q3 		$70.3M Sell
202,231
-182,487
-47% -$63.8M 0.22% 81
2023
Q2 		$135M Sell
384,718
-234,078
-38% -$78.9M 0.47% 37
2023
Q1 		$195M Sell
618,796
-120,191
-16% -$36M 0.69% 25
2022
Q4 		$213M Buy
738,987
+76,752
+12% +$23.4M 0.77% 23
2022
Q3 		$192M Buy
662,235
+146,237
+28% +$42.1M 0.74% 24
2022
Q2 		$145M Sell
515,998
-292,556
-36% -$78.3M 0.54% 33
2022
Q1 		$211M Buy
808,554
+486,323
+151% +$115M 0.59% 32
2021
Q4 		$70.8M Buy
322,231
+252,752
+364% +$49.1M 0.21% 85
2021
Q3 		$12.6M Sell
69,479
-166,649
-71% -$32.5M 0.04% 262
2021
Q2 		$47.6M Sell
236,128
-37,631
-14% -$7.87M 0.16% 113
2021
Q1 		$58.8M Sell
273,759
-324,687
-54% -$71.3M 0.24% 77
2020
Q4 		$141M Buy
598,446
+474,130
+381% +$109M 0.62% 33
2020
Q3 		$33.8M Sell
124,316
-1,314
-1% -$363K 0.19% 90
2020
Q2 		$36.5M Sell
125,630
-641,941
-84% -$174M 0.23% 76
2020
Q1 		$183M Buy
767,571
+498,163
+185% +$114M 1.46% 19
2019
Q4 		$59M Buy
269,408
+240,816
+842% +$48.7M 0.37% 54
2019
Q3 		$4.84M Buy
28,592
+19,333
+209% +$3.42M 0.03% 245
2019
Q2 		$1.7M Sell
9,259
-59,305
-86% -$10.4M 0.01% 572
2019
Q1 		$12.6M Sell
68,564
-315,198
-82% -$58.2M 0.12% 159
2018
Q4 		$63.6M Buy
383,762
+192,494
+101% +$33.4M 0.72% 34
2018
Q3 		$36.9M Sell
191,268
-173,500
-48% -$30.9M 0.36% 64
2018
Q2 		$62M Buy
364,768
+212,481
+140% +$32.9M 0.72% 32
2018
Q1 		$24.8M Sell
152,287
-6,287
-4% -$1.03M 0.32% 82
2017
Q4 		$23.8M Sell
158,574
-734,806
-82% -$109M 0.24% 95
2017
Q3 		$136M Buy
893,380
+883,998
+9,422% +$133M 1.26% 16
2017
Q2 		$1.21M Buy
+9,382
New +$1.13M 0.03% 139

Other funds holding VRTX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Assenagon Asset Management's VRTX Position: Q2 2026 in Review

Assenagon Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 41% in Q2 2026, buying an estimated $98.5M and bringing the position to 759,564 shares worth $377M. The position accounts for 0.47% of the portfolio, ranked #36.

Assenagon Asset Management first reported a position in VRTX in Q2 2017 and has held it in 37 quarters since. The position peaked at $378M in Q4 2025. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Assenagon Asset Management held 759,564 shares of Vertex Pharmaceuticals worth $377M as of Q2 2026.
  • Assenagon Asset Management bought 222,316 Vertex Pharmaceuticals shares in Q2 2026, an estimated $98.5M.
  • Vertex Pharmaceuticals made up 0.47% of Assenagon Asset Management's portfolio in Q2 2026, its #36 holding.
  • Assenagon Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 37 quarters since.
  • Assenagon Asset Management's Vertex Pharmaceuticals position peaked at $378M in Q4 2025.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.